Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain.

We have four products in late-stage development.

MED3000, our lead product, is a topical gel which utilises our proprietary technology DermaSys®, and was developed specifically for the treatment of ED.

Our product pipeline

Lead products

Concept

Development

Commercialisation

Description: Topical gel for erectile dysfunction

Status: Phase 3 clinical trial completed with EU and US regulatory processes underway.

Description: Topical diclofenac pain relief gel

Status: Regulatory dossier submitted in the UK. UK licence partner addressing queries with support from Futura. Licensing discussions for further territories ongoing.

Other products

Concept

Development

Commercialisation

Description: Topical cannabidiol formulation

Status: Joint venture collaboration. Early development stage to explore a number of disease states including pain relief.

Description: Condom containing an erectogenic gel

Status: Approved in the EU, 24 month shelf life

Description: Topical ibuprofen pain relief gel

Status: Out-licencing discussions ongoing